Key regions: Germany, South Korea, France, United States, United Kingdom
The Anti-Coagulants market in Hungary has experienced significant growth in recent years.
Customer preferences: Customers in Hungary are increasingly seeking out medications that are effective in treating blood clots, without causing excessive bleeding or other side effects. As a result, there has been a growing demand for anti-coagulant medications that are both safe and effective.
Trends in the market: One of the key trends in the Hungarian anti-coagulant market is the increasing use of direct oral anticoagulants (DOACs) over traditional vitamin K antagonists (VKAs). DOACs are generally considered to be safer and more effective than VKAs, and they have become increasingly popular among patients in Hungary. Another trend in the market is the growing use of anti-coagulant medications for the prevention of stroke in patients with atrial fibrillation.
Local special circumstances: One of the unique features of the Hungarian anti-coagulant market is the relatively high prevalence of atrial fibrillation among the population. This has led to a greater demand for anti-coagulant medications that are effective in preventing stroke in these patients. Additionally, there is a growing awareness among healthcare providers in Hungary of the importance of preventing blood clots in high-risk patients, which has contributed to the growth of the anti-coagulant market.
Underlying macroeconomic factors: The growth of the anti-coagulant market in Hungary can be attributed to a number of underlying macroeconomic factors. These include the aging population, which has led to an increase in the prevalence of conditions such as atrial fibrillation and deep vein thrombosis. Additionally, the growing burden of non-communicable diseases in Hungary has led to an increased demand for medications that can effectively treat and prevent these conditions. Finally, the increasing availability of DOACs in Hungary has made it easier for healthcare providers to prescribe these medications to patients who require anti-coagulation therapy.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
